Long-term treatment with angiotensin II type 1 receptor antagonist, CV-11974, restores beta-catenin mRNA expression in volume-overloaded rabbit hearts

Heart Vessels. 2002 Nov;17(1):36-41. doi: 10.1007/s003800200040.

Abstract

This study aimed to search genes altered in expression after long-term treatment with the angiotensin II type 1 receptor (AT1) antagonist, CV-11974, in volume-overloaded hearts. Arteriovenous shunt was made between the common carotid artery and jugular vein in Japanese White rabbits. Shunt-operated rabbits were randomly treated with CV-11974 or vehicle for 6 weeks, starting 6 weeks after surgery. As controls, sham-operated rabbits were given vehicle. Total RNA was prepared from each left ventricular myocardium. Using differential display, we screened one cDNA encoding human beta-catenin, in which the expression was upregulated after CV-11974 administration in shunt rabbit hearts. Beta-catenin is a molecule that exists in the intercalated disks and also works in cytoplasm as a major component of Wnt signaling. We then examined mRNA expressions of beta-catenin and connexin43 by semiquantitative reverse transcriptase-polymerase chain reaction (RT-PCR). The mRNA expressions of beta-catenin and connexin43 were markedly depressed in shunt-operated animals given vehicle compared with sham-operated animals (P < 0.01). These results suggest that downregulation of beta-catenin and connexin43 expression might be involved in the process of ventricular remodeling by volume overload. The RT-PCR also demonstrated that beta-catenin mRNA expression was significantly higher in shunt rabbits treated with CV-11974 than in those given vehicle (P < 0.05). These data suggest that volume overload may downregulate beta-catenin expression by an AT1 receptor-mediated pathway.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Angiotensin Receptor Antagonists*
  • Animals
  • Antihypertensive Agents / antagonists & inhibitors*
  • Benzimidazoles / antagonists & inhibitors*
  • Biphenyl Compounds
  • Blood Pressure / drug effects
  • Blood Pressure / physiology
  • Connexin 43 / biosynthesis
  • Connexin 43 / drug effects
  • Cytoskeletal Proteins / biosynthesis*
  • Cytoskeletal Proteins / drug effects*
  • DNA, Complementary / biosynthesis
  • DNA, Complementary / drug effects
  • Disease Models, Animal
  • Heart Rate / drug effects
  • Heart Rate / physiology
  • Hypertrophy, Left Ventricular / metabolism*
  • Hypertrophy, Left Ventricular / physiopathology
  • Hypertrophy, Right Ventricular / metabolism*
  • Hypertrophy, Right Ventricular / physiopathology
  • Japan
  • Male
  • Models, Cardiovascular
  • Myocardial Contraction / drug effects
  • Myocardial Contraction / physiology
  • RNA, Messenger / biosynthesis*
  • RNA, Messenger / drug effects*
  • Rabbits
  • Receptor, Angiotensin, Type 1
  • Stroke Volume / drug effects
  • Stroke Volume / physiology
  • Tetrazoles / antagonists & inhibitors*
  • Time
  • Trans-Activators / biosynthesis*
  • Trans-Activators / drug effects*
  • Ventricular Pressure / drug effects
  • Ventricular Pressure / physiology
  • beta Catenin

Substances

  • Angiotensin Receptor Antagonists
  • Antihypertensive Agents
  • Benzimidazoles
  • Biphenyl Compounds
  • Connexin 43
  • Cytoskeletal Proteins
  • DNA, Complementary
  • RNA, Messenger
  • Receptor, Angiotensin, Type 1
  • Tetrazoles
  • Trans-Activators
  • beta Catenin
  • candesartan